Blood-brain barrier destruction determines Fisher/Bickerstaff clinical phenotypes: An in vitro study

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 84, Issue 7, 2013, Pages 756-765

  Saito, Kazuyuki ^a,b   Shimizu, Fumitaka ^a   Koga, Michiaki ^a   Sano, Yasuteru ^a   Tasaki, Ayako ^a   Abe, Masaaki ^a   Haruki, Hiroyo ^a   Maeda, Toshihiko ^a   Suzuki, Seiko ^c   Kusunoki, Susumu ^c   Mizusawa, Hidehiro ^b   Kanda, Takashi ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 5; GELATINASE A; GELATINASE B; TIGHT JUNCTION PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BICKERSTAFF BRAINSTEM ENCEPHALITIS; BLOOD ANALYSIS; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ELECTRIC RESISTANCE; ENCEPHALITIS; ENZYME ACTIVITY; ENZYME RELEASE; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROVASCULAR ENDOTHELIAL CELL; PATIENT ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

EID: 84878760281     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-304306     Document Type: Article

References (40)

1. Bickerstaff ER, Cloake PC. Mesencephalitis and rhombencephalitis. Br Med J 1951;2:77-81.
2. Bickerstaff ER. Brain-stem encephalitis: further observations on a grave syndrome with benign prognosis. Br med J 1957;1:1384-7.
3. Fisher M. An usual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N Eng J Med 1956;255:57-65.
4. Ito M, Kuwabara S, Odaka M, et al. Bickerstaff's brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J Neurol 2008;255:674-82.
5. Chiba A, Kusunoki S, Shimizu T, et al. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol 1992;31:677-9.
6. Yuki N, Sato S, Tsuji S, et al. An immunologic abnormality common to Bickerstaff's brainstem encephalitis and Fisher's syndrome. J Neurol Sci 1993;118:83-7. (Pubitemid 23269971)
7. Kanda T, Yamawaki M, Mizusawa H. Sera from Guillain-Barré patients enhance leakage in blood-nerve barrier model. Neurology 2003;60:301-6. (Pubitemid 36152027)
8. Kanda T. Biology of the blood-nerve barrier and its alternation in immune mediated neuropaties. J Neurol Neurosurg Psychiatry 2013;84:208-12.
9. Koga M, Kusunoki S, Kaida K, et al. Nationwide survey of patients in Japan with Bickerstaff brainstem encephalitis: epidemiological and clinical characteristics. J Neurol Neurosurg Psychiatry 2012;83:1210-15.
10. Odaka M, Yuki N, Yamada M, et al. Bickerstaff's brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain-Barré syndrome. Brain 2003;126:2279-90. (Pubitemid 37432371)
11. Hughes RAC, Cornbath DR. Guillain-Barré syndrome. Lancet 2005;366:1653-66.
12. Olsson Y. Microenvironment of the peripheral nervous system under normal and pathological conditions. Crit Rev Neurobiol 1990;5:265-311. (Pubitemid 20128523)
13. Sano Y, Shimizu F, Abe M, et al. Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood-brain barrier function. J Cell Physiol 2010;225:519-28.
14. Abe M, Sano Y, Maeda T, et al. Establishment and characterization of human peripheral nerve microvascular endothelial cell lines: a New in vitro Bloood-Nerve Barrier (BNB) Model. Cell Struct Funct 2012;37:89-100.
15. Shimizu F, Sano Y, Takahashi T, et al. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry 2012;83:288-97.
16. Leroy-Dudal J, Demeilliers C, Gallet O, et al. Transmigration of human ovarian adenocarcinoma cells through endothelial extracellular matrix involves αvintegrins and the participation of MMP2. Int J Cancer 2005;114:531-43. (Pubitemid 40349611)
17. Lockwood CJ, Oner C, Uz YH, et al. Matrix metalloproteinase 9 (MMP9) expression in preeclamptic decidua and MMP9 induction by tumor necrosis factor alpha and Interleukin 1 beta in human first trimester decidual cells. Biol Reprod 2008;78:1064-72. (Pubitemid 351749303)
18. Zhang ZL, Liu ZS, Sun Q. Expression of angiopoietins, Tie 2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma. World J Gastroenterol 2006;12:4241-5. (Pubitemid 44376912)
19. Chen W, Hartman R, Ayer R, et al. Matrix metalloproteinases inhibition provides neuroprotection against hypoxia-ischemia in the developing brain. J Neurochem 2009;111:726-36.
20. Thanabalasundaram G, Pieper C, Lischper M, et al. Regulation of the blood-brain barrier integrity by pericytes via matrix metalloproteinase's mediated activation of vascular endothelial growth factor in vitro. Brain Res 2010;1347:1-10.
21. Nyati KK, Prasad KN, Verma A, et al. Correlation of matrix metalloproteinase-2 and -9 with proinfl ammatory cytokines in Guillain-Barré syndrome. J Neurosci Res 2010;88:3540-46.
22. Shimizu F, Sano Y, Abe M, et al. Peripheral nerve pericytes modify the blood-nerve barrier function and tight junctional molecules through the secretion of various soluble factors. J Cell Physiol 2010;226:255-66.
23. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5 deficient mice. J Cell Biol 2003;161:653-60. (Pubitemid 36578587)
24. Kanda T, Iwasaki T, Yamawaki M, et al. Anti-GM1 antibody fascilitates leakage in an in vitro blood-nerve barrier model. Neurology 2000;55:585-7. (Pubitemid 30647264)
25. Kanda T, Yoshino H, Ariga T, et al. Glycosphingolipid antigens in cultured microvascular bovine brain endothelial cells: sulfoglucuronosyl paragloboside as a target of monoclonal IgM in demyelinative neuropathy. J Cell Biol 1994;126:235-46.
26. Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle & Nerve 1999;22:1071-4. (Pubitemid 29360252)
27. Chiba A, Kusunoki S, Obata H, et al. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:1911-17. (Pubitemid 23318855)
28. Chiba A, Kusunoki S, Obata H, et al. Ganglioside composition of the human cranial nerves with special reference to pathophysiology of Miller Fisher syndrome. Brain Res 1997;745:32-6. (Pubitemid 27055743)
29. Liu JX, Willison HJ, Pedrosa-Domellöf F. Immunolocalization of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest Ophthalmol Vis Sci 2009;50:3226-32.
30. Tilling T, Engelbertz C, Decker S, et al. Expression and adhensive properties of basement membrane proteins in cerebral capillary endothelial cell cultures. Cell Tissue Res 2002;310:19-29.
31. Kieseier BC, Kiefer R, Clements JM, et al. Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. Brain 1998;121:159-66. (Pubitemid 28045514)
32. Kieseier BC, Clements JM, Pischel HB, et al. Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome. Ann Neurol 1998;43:427-34. (Pubitemid 28231716)
33. Créange A, Sharshar T, Planchenault T, et al. Matrix metalloproteinase-9 is increased and correlates with severity in Guillain-Barré syndrome. Neurology 1999;53:1683-91. (Pubitemid 29530340)
34. Asahi M, Wang X, Mori T, et al. Effects of Matrix metalloproteinase-9 Gene knock-out on the proteolysis of Blood-Brain Barrier and White matter Components after cerebral Ischemia. J Neurosci 2001;21:7724-32. (Pubitemid 32904971)
35. Asahi M, Sumii T, Fini ME, et al. Matrix metalloproteinase 2 gene knockout has no effect on acute brain injury after focal ischemia. Neuroreport 2001;12:3003-7. (Pubitemid 32882025)
36. Gijbels K, Galargy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteinases. J Clin Invest 1994;94:2177-82. (Pubitemid 24379586)
37. Redford EJ, Smith KJ, Gregson NA, et al. A combined inhibitor of matrix metalloproteinase activity and tumor necrosis factor-α processing attenuates experimental autoimmune neuritis. Brain 1997;120:1895-905. (Pubitemid 27443062)
38. Corkill DJ, Woolley K, Guard S, et al. The effect of a novel inhibitor of tumour necrosis factor-α processing, BB-1101, in experimental autoimmune encephalomyelitis. Br J Pharmacol 1995;(Suppl 116):8P.
39. Sharief MK, Mclean B, Thompson EJ. Elevated Serum Levels of TNF-α in Guillain-Barré syndrome. Ann Neurol 1993;33:591-6. (Pubitemid 23161879)
40. Hadden RDM, Karch H, Hartung HP, et al. Preceding infections, immune factors, and outcome in Guillain-Barré syndrome. Neurolgy 2001;56:758-65. (Pubitemid 32240096)